Keros Therapeutics, Inc (NASDAQ:KROS) Advances Toward Near-Term Clinical Catalysts After Positive Partnership Milestone
![]() |
Keros enters a near-term phase where clinical program updates and partner-triggered payments should shape momentum; balance-sheet strength offsets current operating losses while valuation sits elevated by WMDST standards. |








